A review on barnidipine: A novel calcium antagonist

Cardiovascular Drug Reviews

Volumn 15, Issue 4, 1997, Pages 273-290

  Sakai, Toshiharu ^a,d   Teramura, Toshio ^b   Okamiya, Hideaki ^a   Inagaki, Osamu ^c  

^a Medicinal Safety Laboratories

^b Drug Metabolism Laboratories

^c Pharmacology Laboratories

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

1,4 dihydropyridines; Barnidipine; Calcium antagonists; Mepirodipine; Metabolism; Pharmacokinetics; Pharmacology; Toxicology

Indexed keywords

CALCIUM ANTAGONIST; MEPIRODIPINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENOTOXICITY; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; ISOMER; LD 50; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

EID: 0031398377     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1997.tb00336.x     Document Type: Article

References (55)

1. 14C]nisoldipine in rats, monkey, and swine. Arzneimittel-Forsch 1988;38:1093-1098.
2. Bäärnhielm C, Dahlbäck H, Stånberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol 1986;59:113-122.
3. Beresford P, McGibney D, Humphrey MJ, Macrae PV, Stopher DA. Metabolism and kinetics of amlodipine in man. Xenobiotica 1988; 18:245-254.
4. Collins JJ, Elwell MR, Lamb JC, Manus AG, Heath JE, Makovec GT. Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice. Fundamen Appl Toxicol 1988;11:472-484.
5. Edgar B, Regårdh CG, Johansson L, Lundborg P, Löfberg I, Ronn O. Felodipine kinetics in healthy men. Clin Pharmacol Ther 1985;38:205-211.
6. Fujiwara M, Itou S, Shibata M. Perinatal and postnatal studies in rats given mepirodipine hydrochloride (YM730) orally. Pharmacometrics 1991;42:283-289.
7. Ha HR, Chen J, Freuburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39:321-326.
8. Higgins C, Tesh JM, McAnulty PA, et al. A fertility study of mepirodipine hydrochloride (YM730), a new calcium antagonist in rats. Clin Pharmacol 1991;1:157-165.
9. Higuchi S, Shiobara Y. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 1980;10:447-454.
10. Inagaki O, Shibasaki M, Honda K, et al. Cardiovascular effect of YM-09730-5, an optically pure dihydropyridine calcium antagonist. Jpn J Pharmacol (Suppl) 1986;40:232.
11. Inagaki O, Momose N, Nakagawa C, Honda K. Effects of YM-09730-5, a new calcium antagonist, on blood pressure and vasocontractor response in spontaneously-hypertensive rats. Jpn J Pharmacol (Suppl) 1987; 43:292.
12. Kann J, Krol GJ, Raemsch KD, Burkholder DE, Levitt MJ. Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol 1984;6:S968-973.
13. Kawashima K, Toda H, Oohata H, et al. Antihypertensive and diuretic effects of YM-09730-5, a new calcium antagonist, in stroke-prone spontaneously hypertensive rats. Gen Pharmacol 1991;22:263-266.
14. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984;33:3721-3724.
15. Kobayashi H, Kobayashi S, Inoue A, Oka T, Nakamizo N. Pharmacokinetic study of benidipine hydrochloride in rats and dogs. Arzneimittel-Forsch 1988;38:1750-1753.
16. Kondo S, Kikuchi A, Yamamoto K, et al. Identification of nifedipine metabolites and their determination by gas chromatography. Chem Pharm Bull 1980;28:1-7.
17. 14C]nitrendipine to rats and dogs. Arzneimittel-Forsch 1988;38:1593-1599.
18. Kronbach T, Fisher V, Meyer UA. Cyclosporin metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporin metabolizing enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 1988;43:630-635.
19. Langley MS, Sorkin EM. Nimodipine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 1989;37:669-699.
20. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): A major monooxigenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1992;52:29-34.
21. Mangiardi LC, Hariman RJ, McAllister RG Jr, et al. Electrophysiologic and hemodynamic effects of verapamil. Correlation with plasma drug concentrations. Circulation 1978;57:366-372.
22. Matsuzawa T, Sakai H, Suzuki H, et al. Acute, subacute and chronic toxicity studies with mepirodipine hydrochloride (YM730, LY198561), a new calcium antagonist in rodents. Clin Rep 1990;24:4383-4398.
23. Nakayama K, Kashiwabara S, Yamada S, et al. Assessment in pig coronary artery of long-lasting and potent calcium antagonistic actions of the novel dihydropiridine derivative mepirodipine hydrochloride. Arzneimittel-Forsch 1989;39:50-55.
24. Ohata T, Shibata M. Oral teratology study of mepirodipine hydrochloride (YM730) in rabbits. Clin Rep 1990;24:4335-4340.
25. Ohata T, Shibata M. Oral teratology study of mepirodipine hydrochloride (YM730) in rats. Clin Rep 1990;24:4341-4356.
26. Okamiya H, Kanai K, Yoshida T, et al. Acute, subacute and chronic toxicity studies of mepirodipine hydrochloride (YM730, LY198561) in beagle dogs. Clin Rep 1990;24:4357-4381.
27. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
28. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nitrendipine. In: Scriabine A, Vanov S, Deck K, eds. Nitrendipine. Baltimore: Urbar & Schwarzenberz, 1986:406-421.
29. Rettie AE, Korzetwa KR, Kunze KL, et al. Hydroxyation of warfarin by human cDNA-expressed cytochrome P-450: A role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 1992;5:54-59.
30. Reyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992;52:350-358.
31. Roland M, Tozer TN. Concept and Kinetics. In Clinical Pharmacokinetics: Concepts and Applications, 2nd Edition. Philadelphia: Lea & Febiger, 1989:132-.
32. Rush WR, Alexander O, Hall DJ, Cairncross L, Dow RJ, Graham DJG. The metabolism of nicardipine hydrochloride in healthy male volunteers. Xenabiotica 1986;16:341-349.
33. Sandusky GE, Means JR. Acute and subchronic toxicology of LY-195115 in rats and dogs. Toxicol Lett 1987;38:177-186.
34. Sandusky GE, Franklin RB, Means JR. Acute, subchronic and chronic toxicity of the cardiotonic isomazole in rats. Fundamen Appl Toxicol 1989;13:409-417.
35. Satoh H. Pharmacology and therapeutic effects of mepirodipine. Cardiovasc Drug Rev 1991;9:340-356.
36. Spatzenegger M, Jeager W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Reviews 1995;27:397-417.
37. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol Suppl 7 1988;12:S55-59.
38. Tamazawa K, Arima H, Kojima T, et al. Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrolidinyl-methyl-2,6-dimethyl-4-(m-nitrophenyl)1,4-dihydropyridine- 3,5-dicarboxylate. J Med Chem 1986;29:2504-2511.
39. Terakawa M, Tokuma Y, Shishido A, Noguchi H. Pharmacokinetics of nilvadipine in healthy volunteers. J Clin Pharmacol 1987;27:111-117.
40. Teramura T, Watanabe T, Higuchi S, Hashimoto K. Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium blocker, in the rat, dog and human. Xenobiotica 1995;25:1237-1246.
41. Teramura T, Tokunaga T, Matsumoto H, Watanabe T, Higuchi S. Metabolism of barnidipine hydrochloride, a potent calcium antagonist, in rat and dog. Xenobiotica 1996;26:177-187.
42. Teramura T, Watanabe T, Higuchi S, Hashimoto K. Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. Xenobiotica 1997;26:177-187.
43. Teramura T, Fukunaga Y, van Hoogdalem EJ, Watanabe T, Higuchi S. Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica 1997;27:885-890.
44. Tokuma Y, Sekiguchi M, Niwa T, Noguchi H. Pharmacokinetics of nilvadipine. a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs. Xenobiotica 1987;18:21-28.
45. Urthaler F, James TN. Experimental studies on the pathogenesis of asystole after verapamil in the dog. Am J Cardiol 1979;44:651-654.
46. van Harten J, van Brummelen P, Danhoff M, Lodewijks M, Breimer DD. Pharmacokinetics and haemodynamic effects of nisoldipine and its interaction with cimetidine in healthy volunteers. Acta Pharmacol Toxicol Suppl 5 1986;59:180.
47. Veronese ME. Tolbutamide and phenytoin metabolism by human cytochrome P450s in the CYP2C subfamily. Clin Exp Pharmacol Physiol 1991;18:64.
48. Vinge E, Andersson KE, Brandt L, Ljunggeren B, Nilson LG, Helgesen SR. Pharmacokinetics of nimodipine in patients with aneurysmal subarachmoid haemorrhage. Eur J Clin Pharmacol 1986;30:421-425.
49. Walker DK, Humphrey MJ, Smith DA. Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica 1994;24:243-250.
50. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-361.
51. Weidolf L, Borg KO, Hoffmann KJ. Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse. Xenobiotica 1984;14:657-666.
52. Westwood FR, Iswaran TJ, Greaves P. Pathologic changes in blood vessels following administration of an inotropic vasodilator (ICI 153, 110) to the rat. Fundamen Appl Toxicol 1990;14:797-809.
53. Yamada S, Matsuoka Y, et al. A sustained occupancy in vivo of cardiovascular calcium antagonist receptor by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J Pharmacol Exp Ther 1992;262:589-594.
54. Yuhas EM, Morgan DG, Arena E, Kupp RP, Saunders LZ, Lewis HB. Arterial medial necrosis and hemorrhage induced in rats by intravenous infusion of fenoldopam mesylate, a doparninergic vasodilator. Am J Pathol 1985;119:83-91.
55. Zipes DP, Fischer JC. Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog. Circ Res 1974;34:184-192.